ReNeuron Group plc Preliminary Results (5135J)

TIDMRENE

RNS Number : 5135J

ReNeuron Group plc

29 June 2017

 
  29 June 2017   AIM: RENE 
 

ReNeuron Group plc

("ReNeuron" or "the Company")

Preliminary Results for the Year Ended 31 March 2017

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce its preliminary results for the year ended 31 March 2017.

Highlights in the period

   --      CTX cell therapy candidate for motor disability as a result of stroke: 
   -     Positive Phase II efficacy data in PISCES II clinical trial 
   -     Phase I clinical trial data from PISCES I study published in The Lancet 

- Pivotal Phase III clinical trial planned to commence in US in early 2018, following positive feedback from the FDA

   --      hRPC cell therapy candidate for retinal diseases: 

- Phase I/II clinical trial in retinitis pigmentosa ongoing in US with Phase I data expected later in 2017 and data from enlarged Phase II stage expected in H2 2018

   -     Cryopreserved formulation of hRPC approved by FDA for use in clinical trials 
   -     Phase II clinical trial application planned later in 2017 in cone-rod dystrophy 
   --      CTX cell therapy candidate for critical limb ischaemia: 
   -     Phase I clinical trial completed with no significant adverse safety events reported 
   --      Exosome therapy platform: 

- Positive pre-clinical data with ExoPr0 exosome therapy candidate presented at leading scientific conferences

- Data indicate that ExoPr0 can cross blood-brain barrier and has potential to target multiple diseases

   -     Initial clinical trial application expected in late 2018 in cancer 

-- Loss for the period of GBP15.57 million (2016: loss of GBP11.35 million); cash outflow from operations of GBP12.64 million (2016: outflow of GBP11.92 million); cash, cash equivalents and bank deposits at 31 March 2017 of GBP53.06 million (2016: GBP65.71 million)

Commenting on the results, Olav Hellebø, ReNeuron's CEO, said:

"Our therapeutic development programmes have continued to progress well during the period, the highlight being positive Phase II data from the PISCES II clinical trial of our CTX cell therapy candidate for stroke disability. We are encouraged by the subsequent feedback we have received from the FDA regarding our planned US pivotal Phase III clinical trial with CTX for stroke disability. The unmet medical need in chronic stroke disability is enormous and we are ever closer to being able to offer a potential new therapeutic option to these patients.

"We have made significant advances with our hRPC cell therapy candidate, both in terms of progressing the ongoing US Phase I/II clinical trial in retinitis pigmentosa and obtaining FDA approval for the cryopreserved formulation of this therapeutic candidate, enabling us to expand our ophthalmology programmes into new indications. We have also generated and presented further encouraging pre-clinical data with our ExoPr0 exosome therapy candidate targeting cancer.

"With our stroke programme moving into Phase III clinical development over the coming months and our retinal disease programmes moving into Phase II clinical development later this year, we expect to achieve significant clinical milestones during each of the next three years."

Analyst meeting and webcast

A meeting for analysts will be held at 9.00am today at the offices of Buchanan, 107 Cheapside, London, EC2V 6DN.

For a webcast of the analyst presentation, please log on to the following web address about 10 minutes before 9.00am:

http://vm.buchanan.uk.com/2017/reneuron290617/registration.htm

For further details please contact Buchanan on 020 7466 5000.

A recording of the presentation will be made available on ReNeuron's website, www.reneuron.com.

Enquiries:

 
                                         [phone] 
 ReNeuron                                 8400 
 Olav Hellebø , Chief Executive 
  Officer 
 
   Michael Hunt, Chief Financial 
   Officer 
 
                                           [phone] 
   Buchanan                                           5000 
 Mark Court, Sophie Cowles, Stephanie 
  Watson 
 
 Stifel Nicolaus Europe Limited          [phone] 
  (Nomad and Broker)                      7600 
 Jonathan Senior, Stewart Wallace, 
  Ben Maddison (NOMAD and Broker) 
 
 

About ReNeuron

ReNeuron is a leading, clinical-stage cell therapy development company. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. The Company has therapeutic candidates in clinical development for disability as a result of stroke, for critical limb ischaemia and for the blindness-causing disease, retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for drugs that would otherwise lack adequate capacity to penetrate to their site of action.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.

This announcement contains forward-looking statements with respect to the financial condition, results of operations and business achievements/performance of ReNeuron and certain of the plans and objectives of management of ReNeuron with respect thereto. These statements may generally, but not always, be identified by the use of words such as "should", "expects", "estimates", "believes" or similar expressions. This announcement also contains forward-looking statements attributed to certain third parties relating to their estimates regarding the growth of markets and demand for products. By their nature, forward-looking statements involve risk and uncertainty because they reflect ReNeuron's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of factors could cause ReNeuron's actual financial condition, results of operations and business achievements/performance to differ materially from the estimates made or implied in such forward-looking statements and, accordingly, reliance should not be placed on such statements.

Chairman's and Chief Executive Officer's Joint Statement

Review of programmes

CTX for stroke disability

During the period, we completed dosing and announced positive data in the Phase II clinical trial (PISCES II) of our CTX cell therapy candidate for stroke disability. PISCES II is a single arm, open-label study in patients living with disability resulting from ischaemic stroke. At the time of announcement of the initial data, all 21 patients in the study had completed three-month follow-up, with ten patients followed for six months and three for twelve months.

The study's primary endpoint was for two patients to reach a minimum two-point improvement in the grasping and lifting test, sub-test number 2, of the Action Research Arm Test (ARAT), at three months post-treatment. Three of the 21 patients achieved this at three, six or twelve months respectively after treatment and were within a group of four responders who also showed clinically relevant improvements on the total ARAT score of arm motor performance. Although the ARAT sub-test number 2 study endpoint was not met (as some responses came later than the three-month target), we believe the result is nonetheless highly encouraging.

Strongly positive results were also seen in the other endpoints of the study, with seven patients (33%) showing a clinically relevant improvement on the Modified Rankin Scale (a measure of disability and dependence) and eight patients (38%) showing a clinically relevant improvement on the Barthel Index (a measure of performance in activities of daily living). In total, 15 out of 21 patients had a clinically significant response on at least one efficacy measure. Improvements in the ARAT scores, Modified Rankin Scale and Barthel Index were all sustained throughout the follow up period.

The study also demonstrated that the CTX treatment was well tolerated, with no cell-related adverse events. Longer term safety and efficacy data from the study will be presented at forthcoming stroke and rehabilitation medical conferences. The PISCES II study was part-funded by a regenerative medicine and cell therapy development grant from Innovate UK.

The above PISCES II data was generated after the publication of long term follow up data from our PISCES I stroke clinical trial in The Lancet. The PISCES I study was the first clinical trial of our CTX cell therapy candidate for stroke disability. The Lancet paper describes two-year follow up clinical data relating to the eleven stroke patients treated in the study. Improvements in neurological status and limb function compared with pre-treatment baseline performance were observed in this study within three months of treatment and maintained throughout long term follow up. The CTX treatment was also well-tolerated by the patients in the PISCES I study, with no cell-related or immunological adverse events reported across the four ascending dose levels.

As a result of the positive data reported from both the PISCES I and PISCES II studies, we have consulted the FDA regarding our plans to conduct a randomised, placebo-controlled, pivotal Phase III clinical trial with CTX in the US, in patients with disability post-stroke. As we reported recently, the FDA has responded positively to our proposals regarding the design and conduct of the proposed Phase III clinical trial and, significantly, specifically recommended that we apply for a Special Protocol Assessment (SPA) for the Phase III study. The SPA process is exclusively reserved for studies considered potentially pivotal in support of product marketing label claims.

Based on the FDA's recommendation, we plan to apply for an SPA for our proposed Phase III clinical trial with CTX for stroke disability. As part of our US regulatory strategy, we also plan to apply for Regenerative Medicine Advanced Therapy (RMAT) designation for our CTX cell therapy candidate for stroke disability. The benefits of RMAT designation are similar to those of Breakthrough Therapy designation, including increased interactions with the FDA during development and eligibility for priority review and accelerated marketing approval.

We are now working to finalise the relevant data packages to enable us to submit both the SPA and RMAT designation applications within the broader IND application to commence a Phase III clinical trial with CTX for stroke disability in the US. We expect to make this combined submission in the final quarter of this year, with the study now expected to commence in early 2018, subject to the requisite regulatory approvals. Data from the study are expected about two years later, in early 2020.

Separately, we have consulted with the European Medicines Agency on our plans for the Phase III clinical trial and we have taken the advice received into account when developing our protocol for the study. In this regard, we intend to file a clinical trial application to regulatory authorities in Europe, shortly after the corresponding US submission. Meetings with the Japanese regulatory agency (PDMA) are also ongoing in order to advance our CTX cell therapy candidate for stroke disability in Japan under regulations that offer the potential for conditional marketing approval for cell therapies at an earlier stage of clinical development.

hRPC for retinitis pigmentosa

During the period under review, we completed dosing of the second dose cohort of three patients in the Phase I element of the Phase I/II clinical trial of our human Retinal Progenitor Cell (hRPC) cell therapy candidate for the blindness-causing disease, retinitis pigmentosa (RP). This US study, which is being conducted at Massachusetts Eye and Ear Infirmary in Boston, is an open-label, dose escalation study to evaluate the safety, tolerability and preliminary efficacy of our hRPC stem cell therapy candidate in fifteen patients with advanced RP.

During the period, we also successfully developed a cryopreserved formulation of the hRPC therapeutic candidate. The FDA has recently approved this formulation and we have now started treating patients with it in the ongoing US Phase I/II study clinical trial in RP patients. The ability to cryopreserve our retinal cell therapy candidate at drug product level represents a major step forward for our retinal disease programme and mirrors the earlier breakthrough we achieved with the cryopreservation of our CTX cell therapy candidate. The new proprietary formulation enables the hRP cells to be frozen for shipping and storage and easily thawed at the point of clinical use. This freeze-thaw modality provides a greatly enhanced shelf life for the product, lower prospective cost of goods and the capability to ship the cells for clinical and commercial application anywhere in the world.

The new hRPC cryopreserved formulation has also allowed an expansion of ReNeuron's clinical programmes in ophthalmology. Firstly, we will shortly file an application with the FDA to expand the Phase II element of the ongoing US Phase I/II clinical trial in RP from six to 20 patients. The expanded study is designed to provide the depth and quality of data that, if positive, will allow subsequent progression to a Phase II/III pivotal study in this indication. In order to maintain the pace of patient recruitment and reduce reliance on a single clinical site, we also intend to open up further US clinical sites for this study. As a consequence of these changes, we expect safety and tolerability data from the Phase I part of the RP study in the first nine patients later this year, with longer term safety data as well as efficacy read-outs from the enlarged Phase II part of the study in the second half of 2018.

Secondly, we intend to expand our hRPC retinal disease programmes into a further disease indication, cone-rod dystrophy (CRD). In contrast to RP, where the initial impact is a loss of rods leading to a deterioration in peripheral vision and night vision, CRD is a group of rare eye disorders associated with a loss of cone cells in the retina that initially results in deterioration of central visual acuity and colour vision. CRD frequently affects patients in childhood and has no cure. It is an inherited orphan disease that affects roughly 1 in 40,000 people.

The expansion of our ophthalmology programmes into CRD is part of a broader strategy to evaluate the efficacy of our hRPC therapeutic candidate across a range of genetic diseases of the eye. We intend to file an application to commence a Phase II clinical trial later this year in patients with CRD, to be run alongside the Phase II part of the ongoing RP clinical trial. Data from the CRD study are expected in mid 2019.

CTX for critical limb ischaemia

In order to focus on the significant opportunity presented by our stroke disability programme, our expanded retinal disease programmes and our emerging exosome platform, we have decided to put our programme for critical limb ischaemia on hold for the time being. Patient dosing was recently completed in a Phase I safety study in this indication, with no significant adverse safety events reported post-administration of the CTX cells via intramuscular injection.

Exosome nanomedicine platform

During the period, and subsequently, we have continued to generate and present pre-clinical data relating to our exosome development programme. Exosomes are nanoparticles secreted from all cells including ReNeuron's proprietary CTX stem cell line. They play a key role in cell-to-cell signalling and early research with ExoPr0, our first CTX-derived exosome therapeutic candidate, has demonstrated that it may have a significant effect in regulating cell growth and apoptosis in cancer.

In conjunction with our academic collaborators at the Department of Biochemical Engineering, University College London (UCL), we have presented data relating to the upstream cell culture processes needed to generate our exosomes and the downstream purification methods that can be applied to remove protein and DNA-based impurities from the exosomes at commercially relevant scale. These new methods were shown to yield a three-fold increase in particle protein purity and a more than five-fold increase in particle DNA purity compared with previous purification processes.

In conjunction with UK's Cell and Gene Therapy Catapult, we have also presented data relating to the characterisation of our exosomes to ensure consistency and control during manufacture. The data demonstrated a robust approach to optimising and qualifying assays for micro-RNA components found in the exosomes. The application of robust characterisation and purification methods to our exosome populations will support their future development across multiple potential disease indications.

Finally, we recently presented data relating to the in vivo biodistribution of ExoPr0, using the most common and disease applicable routes of administration to deliver the exosomes. The studies showed that ExoPr0 can be targeted to specific organs and tissues by either local or systemic administration and, most importantly, can penetrate the blood-brain barrier. These findings, together with earlier research results, suggest that there is significant potential to develop ExoPr0 for the treatment of multiple diseases, both as a novel therapeutic candidate and as a drug delivery vehicle.

On the basis of the above progress and subject to continued success with ongoing pre-clinical development work, we expect to be able to reach the clinic with ExoPr0 in late 2018, targeting cancer.

Other activities

Subsequent to the period end, we were awarded a GBP1.8 million grant from Innovate UK to further advance our next generation commercial cell therapy manufacturing capabilities. The grant will fund key process development activities relating to up-scaled commercial manufacture of our cell therapy candidates, including the development of robust manufacturing processes utilising next generation technology and techniques that will enable the production of our therapeutic candidates at a commercial scale. The work will be undertaken by ReNeuron, as lead participant, and our collaborators on the grant, the Cell & Gene Therapy Catapult.

We are also pleased to be an industry participant in the recently launched Future Targeted Healthcare Manufacturing Hub. The Hub, led by UCL and funded by the Engineering and Physical Sciences Research Council, is an industry-academia consortium established to address the manufacturing, business and regulatory challenges to ensure that new targeted biological medicines can be developed quickly and manufactured at a cost affordable to society.

Financial review

Revenues in the year amounted to GBP46k (2016: GBP29k), being royalties from non-therapeutic licensing activities. Grant income of GBP0.85 million (2016: GBP0.53 million) was also recognised in other income.

Research and development costs increased to GBP16.65 million (2016: GBP10.27 million) and accounted for 80% of net operating expenses (2016: 72%). This increase is primarily due to the increased level of clinical trial activity and associated cell manufacturing and process development costs across the Group's therapeutic programmes. Pre-clinical research costs also increased in the period, reflecting the further progression of the Company's exosome programme.

General and administrative expenses increased slightly to GBP4.14 million (2016: GBP4.02 million).

Finance income, which represents income received from the Group's cash and investments and gains from foreign exchange, was GBP1.72 million in the period (2016: GBP0.88 million). The increase in finance income reflects the increase in average cash and investment balances compared with the equivalent prior period, as well as a favourable movement in exchange rates during the period on cash and investments held in foreign currency.

The total tax credit for the period was GBP2.59 million, relating to an accrual for a research and development tax credit for the period (2016: GBP1.49 million). The increase on the previous year reflects the increase in applicable costs.

As a result of the above, the total comprehensive loss for the year increased to GBP15.57 million (2016: GBP11.35 million).

Cash outflow from operating activities was GBP12.64 million (2016: GBP11.92 million), largely reflecting the operating costs incurred during the period. Capital expenditure was GBP0.53 million (2016: GBP0.29 million). The Group had cash, cash equivalents and bank deposits totalling GBP53.06 million at the year-end (2016: GBP65.71 million).

Summary and outlook

Our therapeutic development programmes have continued to progress well during the period, the highlight being positive Phase II data from the PISCES II clinical trial of our CTX cell therapy candidate for stroke disability. We are encouraged by the subsequent feedback we have received from the FDA regarding our planned US pivotal Phase III clinical trial with CTX for stroke disability. The unmet medical need in chronic stroke disability is enormous and we are ever closer to being able to offer a potential new therapeutic option to these patients.

We have made significant advances with our hRPC cell therapy candidate, both in terms of progressing the ongoing US Phase I/II clinical trial in retinitis pigmentosa and obtaining FDA approval for the cryopreserved formulation of this therapeutic candidate, enabling us to expand our ophthalmology programmes into new indications. We have also generated and presented further encouraging pre-clinical data with our ExoPr0 exosome therapy candidate targeting cancer.

With our stroke programme moving into Phase III clinical development over the coming months and our retinal disease programmes moving into Phase II clinical development later this year, we expect to achieve significant clinical milestones during each of the next three years.

John Berriman Olav Hellebø

Chairman Chief Executive Officer

29 June 2017

Group Statement of Comprehensive Income for the year ended 31 March

 
                                                  2017        2016 
                                               GBP'000     GBP'000 
-------------------------------------  ---  ----------  ---------- 
 Revenue: royalty income                            46          29 
 Other income: grants                              854         534 
 Research and development costs               (16,648)    (10,272) 
 General and administrative costs              (4,139)     (4,015) 
------------------------------------------  ----------  ---------- 
 Operating loss                               (19,887)    (13,724) 
 Finance income                                  1,722         878 
------------------------------------------  ----------  ---------- 
 Loss before income tax                       (18,165)    (12,846) 
 Income tax credit                               2,592       1,492 
------------------------------------------  ----------  ---------- 
 Loss and total comprehensive loss 
  for the year                                (15,573)    (11,354) 
------------------------------------------  ----------  ---------- 
 
 Loss and total comprehensive loss 
  attributable to equity owners of 
  the Company                                        2 
                                              (15,573)    (11,354) 
 -----------------------------------------  ----------  ---------- 
 
 Basic and diluted loss per ordinary 
  share                                         (0.5p)      (0.4p) 
------------------------------------------  ----------  ---------- 
 

Group Statement of Financial Position as at 31 March

 
 
                                        2017       2016 
                                     GBP'000    GBP'000 
--------------------------------   ---------  --------- 
 Assets 
 Non-current assets 
 Property, plant and equipment           724        361 
 Intangible assets                         -      1,591 
 Investments - bank deposit                -      5,000 
 Trade and other receivables               -         11 
---------------------------------  ---------  --------- 
                                         724      6,963 
 --------------------------------  ---------  --------- 
 Current assets 
 Trade and other receivables           1,060      1,421 
 Income tax receivable                 4,015      2,764 
 Investments - bank deposit           24,936     43,283 
 Cash and cash equivalents            28,125     17,426 
---------------------------------  ---------  --------- 
                                      58,136     64,894 
 --------------------------------  ---------  --------- 
 Total assets                         58,860     71,857 
---------------------------------  ---------  --------- 
 
 Equity 
 Equity attributable to owners 
  of the Company 
 Share capital                        31,646     31,646 
 Share premium account                97,704     97,704 
 Capital redemption reserve            8,964      8,964 
 Merger reserve                        2,223      2,223 
 Accumulated losses                 (87,380)   (72,879) 
---------------------------------  ---------  --------- 
 Total equity                         53,157     67,658 
---------------------------------  ---------  --------- 
 
 Liabilities 
 Non-current liabilities 
 Financial liabilities: finance            1          - 
  leases 
--------------------------------   ---------  --------- 
                                           1          - 
--------------------------------   ---------  --------- 
 Current liabilities 
 Trade and other payables              5,701      3,700 
 Provisions                                -        498 
 Financial liabilities: finance 
  leases                                   1          1 
---------------------------------  ---------  --------- 
                                       5,702      4,199 
 --------------------------------  ---------  --------- 
 Total liabilities                     5,703      4,199 
---------------------------------  ---------  --------- 
 Total equity and liabilities         58,860     71,857 
---------------------------------  ---------  --------- 
 

Group Statement of Changes in Equity

 
                                         Share      Capital 
                               Share   Premium   redemption    Merger   Accumulated      Total 
                             capital   Account      reserve   reserve        losses     equity 
                             GBP'000   GBP'000      GBP'000   GBP'000       GBP'000    GBP'000 
 As at 1 April 2015           17,888    46,267        8,964     2,223      (62,206)     13,136 
 Issue of Ordinary 
  shares                      13,758    54,696            -         -             -     68,454 
 Costs of share issue              -   (3,259)            -         -             -    (3,259) 
 Credit on share-based 
  payment                          -         -            -         -           681        681 
 Loss for the year 
  and total comprehensive 
  loss                             -         -            -         -      (11,354)   (11,354) 
 As at 31 March 2016          31,646    97,704        8,964     2,223      (72,879)     67,658 
 
 Credit on share-based 
  payment                          -         -            -         -         1,072      1,072 
 Loss for the year 
  and total comprehensive 
  loss                             -         -            -         -      (15,573)   (15,573) 
 As at 31 March 2017          31,646    97,704        8,964     2,223      (87,380)     53,157 
--------------------------  --------  --------  -----------  --------  ------------  --------- 
 
 
 Group Statement of Cash Flows for 
  the year ended 31 March 
 
 
                                                2017       2016 
                                             GBP'000    GBP'000 
 Cash used in operations                    (13,976)   (11,920) 
 Income tax credit received                    1,340          - 
 Cash used in operating activities          (12,636)   (11,920) 
 
 Cash flows from investing activities 
 Capital expenditure - Fixed Assets            (532)      (293) 
 Interest received                               520        345 
 Net cash (used)/generated in investing 
  activities                                    (12)         52 
 
 Cash flows from financing activities 
 Finance lease principal payments 
 Proceeds from issuance of Ordinary 
  shares                                           -     68,454 
 Costs of share issue                              -    (3,259) 
 Bank deposit matured/(placed)                23,347   (48,283) 
 Net cash generated from financing 
  activities                                  23,347     16,912 

-----------------------------------------  ---------  --------- 
 
 Net increase in cash and cash 
  equivalents                                 10,699      5,044 
 Cash and cash equivalents at the 
  start of year                               17,426     12,382 
 Cash and cash equivalents at the 
  end of year                                 28,125     17,426 
-----------------------------------------  ---------  --------- 
 

Notes to the financial information for the year ended 31 March 2017

   1.            General information 

ReNeuron Group plc ("the Company") and its subsidiaries (together "the Group") are engaged in the research and development of therapies using stem cells. The Company is a public limited company incorporated and domiciled in England with registered number 05474163. Its shares are listed on the Alternative Investment Market (AIM) of the London Stock Exchange.

   2.            Basis of preparation 

The unaudited financial information included in this preliminary results announcement for the year ended 31 March 2017 and audited financial information for the year ended 31 March 2016 does not comprise statutory accounts within the meaning of section 434 of the Companies Act 2006. The information has been extracted from the draft statutory financial statements for the year ended 31 March 2017 which will be delivered to the Registrar of Companies in due course. Statutory financial statements for the year ended 31 March 2016 were approved by the Board of directors on 22 July 2016 and have been delivered to the Registrar of Companies. The report of the auditors on these financial statements was unqualified and did not include an emphasis of matter paragraph.

The financial statements have been prepared in accordance with International Financial Reporting Standards (IFRSs) as adopted by the European Union, the interpretations of International Financial Reporting Interpretations Committee (IFRIC) and the Companies Act 2006 applicable to companies reporting under IFRS.

Whilst the financial information included in this preliminary announcement has been prepared in accordance with International Financial Reporting Standards (IFRS), this announcement does not contain sufficient information to comply with IFRS. The accounting policies used in the preparation of these unaudited financial statements are consistent with those used in the preparation of the audited financial statements for the year ended 31 March 2016.

   3.            Going concern 

The Group is expected to incur significant further costs as it continues to develop its therapies and technologies through clinical development and as it establishes a cell manufacturing facility in South Wales.

In August 2015, the Company raised GBP68.4 million, before expenses, by means of a Placing to shareholders. The directors expect that the Group's current financial resources will be sufficient to support operations for at least the next 12 months. Consequently, the going concern basis has been adopted in the preparation of these financial statements.

   4.            Research and development costs 

All research and development costs incurred in the year have been charged directly to the Group Statement of Comprehensive Income.

   5.            Basic and diluted loss per ordinary share 

The basic and diluted loss per share is calculated by dividing the loss for the financial year of GBP15,573,000 (2016: GBP11,354,000) by 3,164,618,541 shares (2016: 2,609,315,899 shares), being the weighted average number of 1p Ordinary shares in issue during the year.

Potential Ordinary shares are not treated as dilutive as the entity is loss making.

   6.            Cash used in operating activities for the year ended 31 March 
 
 
                                                  2017       2016 
                                               GBP'000    GBP'000 
  Loss before income tax                      (18,165)   (12,846) 
  Adjustment for: 
  Interest received                              (520)      (345) 
  Depreciation of property, plant 
   and equipment                                   170         92 
      Impairment of intangible assets            1,591          - 
     Provisions movement                         (498)      (107) 
     Share-based payment charges                 1,072        681 
 
  Changes in working capital: 
  Receivables                                      372      (751) 
  Payables                                       2,002      1,356 
  Cash used in operating activities           (13,976)   (11,920) 
 -----------------------------------------   ---------  --------- 
 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

FR ZMGZVKLRGNZG

(END) Dow Jones Newswires

June 29, 2017 02:01 ET (06:01 GMT)